メロキシカム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H301：飲み込むと有毒

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P310：飲み込んだ場合：直ちに医師に連絡すること。

  P405：施錠して保管すること。

  P501：内容物/容器を．．．に廃棄すること。

メロキシカム 価格

MSDS Information

• Meloxicam

メロキシカム 化学特性,用途語,生産方法

• 外観

  白色～黄色, 結晶性粉末～粉末

• 溶解性

  DMFに溶け、アセトンには加温後溶け、エタノール及び水に溶けない。

• 用途

  メロキシカム(Meloxicam)は、鎮痛剤及び解熱剤の効果を持つ非ステロイド性抗炎症薬である。

• 用途

  メロキシカム(Meloxicam)は、鎮痛剤及び解熱剤の効果を持つ非ステロイド性抗炎症薬である。オキシカムの誘導体で、ピロキシカムと近い関係にあり、エノール型である。 メロキシカムは、プロスタグランジン合成の第1段階として、アラキドン酸を炎症を仲介するプロスタグランジンH2に変換するシクロオキシゲナーゼを阻害する。メロキシカムは、特に低投与量では、プロスタグランジンエンドペルオキシドシンターゼ1(COX-1)よりもプロスタグランジンエンドペルオキシドシンターゼ2(COX-2)に対する選択性を持つ。 滑液中のメロキシカム濃度は、血漿の40%から50%の範囲である。滑液中にはアルブミンが少ないため、滑液の遊離画分は、血漿の2.5倍も高い。この浸透の重要性は未知であるが、恐らく動物モデルで関節炎の治療に非常に有効な原因になっていると考えられる。

• 用途

  薬理・生理作用研究用。

• 用途

  オキシカム系化合物です。シ クロオキシゲナーゼ2（COX-2）を選択的に 阻害し、プロスタグランジン生合成抑制作用 を示します。

• 用途

  オキシカム系化合物です。シ クロオキシゲナーゼⅡ（COX- Ⅱ）を選択的 に阻害し、プロスタグランジン生合成抑制作 用を示します。

• 効能

  鎮痛薬, 抗炎症薬, シクロオキシゲナーゼ2阻害薬

• 商品名

  モービック (日本ベーリンガーインゲルハイム)

• 説明

  Known as a nonsteroidal anti-inflammatory drug (NSAID), Meloxicam is commonly used to treat pain or inflammation caused by rheumatoid arthritis and osteoarthritis in adults. It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old. It is effective to reduce pain, inflammation, swelling, and stiffness of the joints. Developed by Boehringer-Ingelheim, Meloxicam is a derivative of oxicam that can relieve the symptoms of arthritis, primary dysmenorrhea, fever with analgesic and antipyretic properties. Meloxicam was approved for use in April 2000.
  Anti-inflammatory effects of meloxicam function by inhibiting the prostaglandin synthetase (cyclooxygenase 1 and 2) which results in a decrease of the synthesis of prostaglandins. As prostaglandins are chemicals that contribute to inflammation especially within joints, which leads to the common symptoms of pain, tenderness, and swelling associated with arthritis, inhibition of their synthesis can be associated with the analgesic and antipyretic effects of meloxicam. As a result, inflammation and its accompanying symptoms are reduced. Meloxicam starts to relieve pain about 30 to 60 minutes after administration.

• 化学的特性

  Meloxicam is a light yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)app = 0.1 in n-octanol/buffer pH 7.4. It has pKa values of 1.1 and 4.2.

• 使用

  Meloxicam is a preferential cyclooxygenase (COX-2) inhibitor that used for symptomatic treatment of arthritis and osteoarthritis. Sudoxicam and Meloxicam are nonsteroidal anti-inflammatory drugs (NSAIDs) from the enol-carboxamide class.

• 定義

  ChEBI: Meloxicam is a benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug, an antirheumatic drug, a cyclooxygenase 2 inhibitor and an analgesic. It is a benzothiazine, a monocarboxylic acid amide and a member of 1,3-thiazoles.

• 適応症

  Meloxicam (Mobic), recently introduced for the treatment of osteoarthritis, is also used for rheumatoid arthritis and certain acute conditions. Although meloxicam is sometimes reported to be a selective COX-2 inhibitor, it is considerably less selective than celecoxib or rofecoxib. Its adverse effects are similar to those of piroxicam and other NSAIDs; however, the frequency of GI side effects is lower for meloxicam than for piroxicam and several other NSAIDs.

• 一般的な説明

  Meloxicam (Mobic) is a selective COX-2 inhibitor amongoxicams indicated for use in RA and OA. It also has a relativelylong half-life of 15 to 20 hours and has a much lowerrate of serious GI side effects and a lower than average riskof nephropathy when compared with other conventionalNSAIDs.196 The recommended dose is 7.5 mg once dailywith a maximum of 15 mg/d. Meloxicam is metabolized inhumans mainly by CYP2C9 (with a minor contribution viaCYP3A4) to 5'-hydroxymethylmeloxicam and 5 carboxymeloxicam.
  In large-scale comparative trials, meloxicam was foundto be at least as effective as most conventional NSAIDs inthe treatment of rheumatic disease or postoperative pain, buthas demonstrated a more favorable GI tolerability profile.

• 生物活性

  Meloxicam is a selective inhibitor of COX-2 (IC50s = 11.8 and 143 μM for COX-2 and COX-1, respectively, in an enzyme activity assay) and a non-steroidal anti-inflammatory drug (NSAID). Meloxicam (0.03%) reduces croton oil-induced increases in TNF-α and IL-1β mRNA levels and increases IL-10 mRNA levels in cornea in a rabbit model of acute ocular inflammation. It inhibits pleural plasma exudation in a carrageenan-induced rat model of pleurisy when administered at a dose of 3 mg/kg. In a canine model of unilateral osteoarthritis of the right stifle joint, meloxicam reduces prostaglandin E2 (PGE2) levels in plasma and right stifle joint synovial fluid when administered at a dose of 0.2 mg/kg. Formulations containing meloxicam have been used in the treatment of osteoarthritis and rheumatoid arthritis.

• 臨床応用

  In April 2000, the U.S. FDA approved meloxicam for the treatment of osteoarthritis. When meloxicam was initially introduced in the United Kingdom, it was promoted as a selective COX-2 inhibitor.

• 副作用

  Meloxicam may cause stomach upset, nausea, dizziness or diarrhoea, increased blood pressure, headache, easy bruising or bleeding; mental or mood changes; signs of kidney problems (e.g., changes in urine output), unexplained stiffness of the neck, symptoms of heart failure (e.g., swelling of the ankles or feet; unusual tiredness, unusual weight gain).
  Meloxicam rarely causes serious (potentially fatal) liver disease. Include: nausea or vomiting, loss of appetite, dark-coloured urine, stomach or abdominal pain, and yellowing of the eyes or skin.
  Very serious allergic reactions to Meloxicam are rare. Include: fever, swollen lymph nodes, rash, itching or swelling (especially of the face or tongue or throat), severe dizziness, and difficulty breathing. However, if you notice any symptoms of a severe allergic reaction, seek medical help immediately.

• 代謝

  Meloxicam, however, is less selective than celecoxib and much less selective than rofecoxib in in vitro studies. Meloxicam is readily absorbed when administered orally and is highly bound to plasma proteins. Meloxicam is extensively metabolized in the liver, primarily by CYP2C9 and, to a lesser extent, by CYP3A4. The advantages of meloxicam over celecoxib and rofecoxib in the treatment of osteoarthritis (or rheumatoid arthritis) are not readily apparent.

• Mode of action

  Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), by shutting down prostaglandin synthesis, it has antiinflammatory, antipyretic and analgesic properties. This is accomplished by preferentially inhibiting the COX-2 system relative to the COX-I which also leads to an improved GI safety profile relative to naproxen, diclofenac and prioxicam. It can also interfere with neutrophil function like degranulation. Meloxicam did not inhibit proteoglycan synthesis in osteroarthitic cartilage or chondrocytes and had no effect on platelet aggregation. It is metabolized by the P450 2C9 system into four metabolites which are all inactive.

• 参考文献

  [1] https://en.wikipedia.org/wiki/Meloxicam
  [2] https://www.drugbank.ca/drugs/DB00814
  [3] https://www.drugs.com/meloxicam.html
  [4] http://www.medicinenet.com/meloxicam/article.htm
  [5] K OGINO. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.[J]. Pharmacology, 1997, 55 1: 44-53. DOI:10.1159/000139511.
  [6] CHRISTOPHER J JONES. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs.[J]. American journal of veterinary research, 2002, 63 11: 1527-1531. DOI:10.2460/ajvr.2002.63.1527.
  [7] S NOBLE J A B. Meloxicam.[J]. Drugs, 1996, 51 3: 424-430; discussion 431-32. DOI:10.2165/00003495-199651030-00007.
  [8] BANDOO C CHATALE Mariam S D. Synthesis and in-vivo taste assessment of meloxicam pivalate.[J]. Drug Development and Industrial Pharmacy, 2019, 45 10: 1590-1598. DOI:10.1080/03639045.2019.1628250.

メロキシカム 上流と下流の製品情報

メロキシカム 生産企業

Global(655)Suppliers

メロキシカム スペクトルデータ(¹HNMR)

71125-38-7, メロキシカム キーワード